Phase IB study of sorafenib + evofosfamide in patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma NCCTG N1153 (Alliance) Borad, Mitesh J. , Foster, Nathan R. , Martin, Peter R. ... - ESMO GI - Ann. Oncol. - 2016 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N1153
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett, Wendy R , McCall, Linda M , Petersen, Rebecca P ... - - J. Clin. Oncol. - 2006 Manuscript - Primary Endpoint - Primary Analysis - Experimental - Z0020
Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). D'Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091103
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma† Dickson, M. A. , Mahoney, M. R. , Tap, W. D. , D'Angelo, S. P. ... - - Ann. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091102
Alliance A091102: Phase II study of MLN8237 (alisertib) in advanced/metastatic sarcoma Dickson, Mark Andrew , Mahoney, Michelle R. , Marchello, Benjamin T. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091102
N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM) Dronca, R. , Perez, D. , Allred, J. , Maples, W. , Creagan, E. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0675
Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma Dronca, Roxana S. , Allred, Jacob B. , Perez, Domingo G. ... - - Am. J. Clin. Oncol. - 2014 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0675
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Cancer Chemother. Pharmacol. - 2015 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091103
A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - Lancet Oncol. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091401
A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401) D’Angelo, Sandra P. , Mahoney, Michelle R. , Van Tine, Brian ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091401
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104) Gajewski, T. F. , Salama, A. K. , Niedzwiecki, D. , Johnson, J. ... - - J Transl Med - 2012 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-500104
Use of gene expression profiling to identify responsive patients treated with carboplatin (Carb), paclitaxel (Pac), and everolimus as first-line treatment for cancer of unknown primary (CUP): NCCTG N0871 (Alliance) Goetz, M. , Foster, N. , Meyers, J. , Steen, P. , Visscher, D. ... - - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0871
Sorafenib for Advanced and Refractory Desmoid Tumors Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - N. Engl. J. Med. - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091105
Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105) Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091105
Alliance A091104: A Phase II Trial of MK-2206 in patients with progressive, recurrent/metastatic adenoid cystic carcinoma Ho, Alan L , Foster, Nathan R. , Meyers, Jeffrey P. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091104
Alliance A091404: a phase II study of enzalutamide (nsc# 766085) for patients with androgen receptor positive salivary cancers Ho, Alan Loh , Foster, Nathan R. , Zoroufy, Alex J. , Worden, Francis ... - ASCO - J. Clin. Oncol. - 2019 Abstract - Primary Endpoint - Primary Analysis - Experimental - A091404
Gemcitabine (G) and irinotecan (CPT-11) as first-line therapy for carcinoma (ca) of unknown primary (CUP): An NCCTG phase II trial Holtan, S. G. , Foster, N. R. , Erlichman, C. E. , Aubry, M. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N004E
Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial Holtan, Shernan G. , Steen, Preston D. , Foster, Nathan R. ... - - PLoS ONE - 2012 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N004E
Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. Jaeckle, K A , Decker, P A , Ballman, K V , Flynn, P J , Giannini, C ... - - J. Neurooncol. - 2011 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Experimental - Comprehensive , NCCTG-85-72-51 , NCCTG-86-03-51 , NCCTG-88-72-02 , NCCTG-88-72-52 , NCCTG-90-72-01 , NCCTG-91-72-01 , NCCTG-92-72-03 , NCCTG-93-72-02 , NCCTG-93-72-52 , NCCTG-88-72-51 , NCCTG-89-72-51 , NCCTG-89-72-52 , NCCTG-91-72-51 , NCCTG-92-72-51 , NCCTG-93-72-51 , NCCTG-95-72-53 , NCCTG-98-72-54 , N997B , NCCTG-84-72-51 , NCCTG-86-72-02 , NCCTG-86-72-53 , N0074 , N0272 , NCCTG-98-72-52 , NCCTG-86-72-51 , NCCTG-98-72-51 , NCCTG-96-72-51
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: A pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trials Jatoi, Aminah , Foster, Nathan R. , Egner, James R. ... - - Int. J. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N064C
A phase I/II trial adding the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel in patients with locoregionally advanced squamous cell carcinoma of the head and neck (HNSCC) Alliance A091101 Jelinek, Michael J. , Foster, Nathan R. , Zoroufy, Alex J. ... - ASCO - J Clin Oncol - 2018 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091101
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Korn, Edward L , Liu, Ping-Yu , Lee, Sandra J ... - - J. Clin. Oncol. - 2008 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N9975
A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E. Kottschade, L. , Suman, V. , Amatruda, T. , Mcwilliams, R. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - N057E
A randomized phase II trial of temozolomide (TMZ) and bevacizumab (BEV) or nab-paclitaxel (nab-P)/carboplatin (CBDCA) and bevacizumab (BEV) in patients with unresectable stage IV metastatic melanoma: A North Central Cancer Treatment Group Study (N0775) Kottschade, L. , Suman, V. , Perez, D. , Mcwilliams, R. , Kaur, J. ... - - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Primary Analysis - Experimental - N0775
A randomized phase II study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N0775 Kottschade, Lisa A. , Suman, Vera J. , Perez, Domingo G. ... - - Cancer - 2013 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0775
A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma- A North Central Cancer Treatment Group Study, N057E1 Kottschade, Lisa A , Suman, Vera J. , Amatruda, Thomas ... - - Cancer - 2011 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N057E
A randomized phase II study of paclitaxel (P), carboplatin (C), bevacizumab (B) +/- everolimus (E) in metastatic melanoma (MM): secondary analysis of outcomes in patients who harbor an NRAS mutation NCCTG N0879 (Alliance). Kottschade, Lisa , Allred, Jacob , Rumila, K. , Markovic, Svetomir ... - SMR - - 2017 Abstract - Secondary Endpoint - Primary Analysis - Experimental - N0879
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Lewis, Lionel D , Miller, Antonius A , Rosner, Gary L ... - - Clin. Cancer Res. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-9871
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). Lichtman, Stuart M , Hollis, Donna , Miller, Antonius A ... - - J. Clin. Oncol. - 2006 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-9762
Randomized phase II study comparing the met inhibitor cabozantinib to temozolomide (tmz) or dacarbazine (dtic) in ocular melanoma - A091201 Luke, Jason J. , Allred, Jacob B. , Horvath, Laura E. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Preliminary Analysis - Experimental - A091201
Randomized phase II trial and tumor mutational spectrum analysis from cabozantinib versus chemotherapy in metastatic uveal melanoma (Alliance A091201) Luke, Jason J. , Olson, Daniel J. , Allred, Jacob B. ... - - Clin. Cancer Res. - 2020 Manuscript - Primary Endpoint - Primary Analysis - Experimental - A091201
A randomized phase ii study of anti-PD-1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605) Luke, Jason , Chmura, Steven , Salama, Joseph , Al-Hallaq, Hania ... - ASCO - J Clin Oncol - 2018 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Experimental - A091605
A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E Markovic, S. N. , Suman, V. J. , Kottschade, L. A. , Amatruda, T. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Experimental - N057E
Aerosolized sargramostim for the treatment of metastatic melanoma to the lungs Markovic, S. , Suman, V. , Schaefer, P. , Rowland, K., Jr ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Experimental - N0071
A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG study1 Markovic, Svetomir N. , Suman, Vera J. , Nevala, Wendy K. ... - - Am J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0071
NCCTG N0879 (Alliance): A randomized phase II trial of carboplatin, paclitaxel, bevacizumab, with or without everolimus for therapy of metastatic malignant melanoma McWilliams, Robert R. , Allred, Jake , Kottschade, Lisa ... - ECC - Eur. J. Cancer - 2015 Abstract - Primary Endpoint - Primary Analysis - Experimental - N0879
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma. McWilliams, Robert R , Allred, Jacob B , Slostad, Jessica A ... - - Cancer - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0879
Pharmacokinetic (PK) and phase I study of sorafenib (S) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction (HD or RD): CALGB 60301 Miller, A. A. , Murry, D. J. , Owzar, K. , Hollis, D. R. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Experimental - CALGB-60301
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301 Miller, Antonius A. , Murry, Daryl J. , Owzar, Kouros ... - - J. Clin. Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-60301
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. Miller, Antonius A , Murry, Daryl J , Owzar, Kouros , Hollis, Donna R ... - - J. Clin. Oncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-60101
Correlates of overall survival (OS) in metastatic vs. primary uveal melanoma (UM) and results of a randomized trial of cabozantinib (cabo) vs. chemotherapy (chemo) Alliance A091201 Olson, Daniel J. , Bao, Riyue , Allred, Jacob B. , Strand, Carrie A. ... - ASCO - J Clin Oncol - 2019 Abstract - Secondary Endpoint - Primary Analysis - Experimental - A091201
CALGB 60104: Adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907 Partridge, A. H. , Archer, L. E. , Kornblith, A. B. , Gralow, J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Experimental - C60104
Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104 Partridge, Ann H. , Archer, Laura , Kornblith, Alice B. ... - - J Clin Oncol - 2010 Manuscript - Primary Endpoint - Primary Analysis - Experimental - CALGB-60104 , CALGB-49907
Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma Perez, D. , Suman, V. , Amatruda, T. , Gornet, M. , Morton, R. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Experimental - N047A
Phase II Trial of Carboplatin, Weekly Paclitaxel and Biweekly Bevacizumab in Patients with Unresectable Stage IV Melanoma – A North Central Cancer Treatment Group (NCCTG) Study, N047A1 Perez, Domingo G. , Suman, Vera J. , Fitch, Tom R. , Amatruda, Thomas ... - - Cancer - 2009 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N047A
Results of NCCTG phase II trial of the mTOR inhibitor RAD-001 in metastatic melanoma Rao, R. D. , Allred, J. B. , Windschitl, H. E. , Maples, W. J. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Experimental - N0377
Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907) Ruddy, K. J. , Pitcher, B. N. , Archer, L. E. , Cohen, H. J. ... - - Ann. Oncol. - 2012 Manuscript - Secondary Endpoint - Primary Analysis - Experimental - CALGB-49907 , CALGB-60104
Results of NCCTG N0275 (Alliance) – a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma Rule, William G. , Allred, Jacob B. , Pockaj, Barbara A. ... - - Cancer Med - 2016 Manuscript - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0275
A phase I/randomized phase II study of MLN0128 vs. Pazopanib in patients with locally advanced/unresectable and/or metastatic sarcoma: Alliance A091304 Tap, William , Mahoney, Michelle , Horvath, Elise ... - ASCO - J. Clin. Oncol. - 2016 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Experimental - A091304
Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance) Vera Aguilera, Jesus , Rao, Ravi D. , Allred, Jacob B. ... - - Oncologist - 2018 Manuscript - Primary Endpoint - Primary Analysis - Experimental - N0377
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (Alliance) Yoon, H. H. , Foster, N. R. , Meyers, J. P. , Steen, P. D. ... - - Ann. Oncol - 2016 Manuscript - Primary Endpoint - Primary Analysis - Experimental - NCCTG-N0871
